CA-INSEEGO-CORP
Inseego Corp. (Nasdaq: INSG), a leader in 5G and intelligent IoT device-to-cloud solutions, today announced that its new Wavemaker PRO 5G indoor router has been certified for use in Europe, North America* and Australia, with additional regulatory certifications pending for other international markets. Designed specifically for enterprise customers, this router combines high-performance, multi-carrier 5G and Wi-Fi 6 connectivity with cloud software that simplifies device management, maximizes security and minimizes expenses for enterprise users.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005447/en/
“Our Wavemaker PRO 5G solutions are changing the way enterprise and SMB customers think about broadband access,” said Inseego President Ashish Sharma. “Whether they have remote branch offices needing faster primary communications, retail locations needing failover solutions, or a distributed workforce needing dependable and secure work-from-home access to their corporate network, the FG2000e router can deliver unmatched speed, throughput and reliability — along with software solutions that make it easy for IT organizations to deploy and manage their devices, protect their networks, and reap the benefits of a multi-carrier 5G managed WAN.”
Bringing 5G enterprise solutions to global markets
The Wavemaker PRO 5G indoor router FG2000e has now received industry certifications that make it commercially available for deployments in many global markets. It’s important to understand that different countries and regions require different types of regulatory and 3GPP certifications in order to operate 5G products on mobile networks. For example, GCF certification demonstrates that products conform with 3GPP standards and will be interoperable with mobile networks worldwide. CE certification means that solutions can be sold to service providers and enterprise customers in over 30 countries of the European Economic Area (EEA) and European Free Trade Association (EFTA). RCM certification verifies that electrical and wireless equipment can be sold in Australia. And FCC certification requires a rigorous process of testing before RF products can be sold and marketed in the U.S.
Having completed all of these certifications, the FG2000e router can now be sold to service providers and enterprise customers across all of these regions, including organizations that are deploying 5G private networks.
New global channel partners
In addition to partnering with service providers, Inseego is expanding its network of distributors, resellers and system integrators worldwide to create new channels to market, along with local market support for its new enterprise solutions. The FG2000e router and software provides local language support, including English, French, Italian, Spanish, German, Arabic and Japanese.
A multi-carrier 5G cloud managed WAN for ubiquitous broadband connectivity
The Wavemaker PRO 5G indoor router FG2000e provides high-performance 5G connectivity and 4G LTE fallback, with features such as:
- Unlocked, dual-SIM, multi-carrier firmware that provides flexibility and ultimate control of the network the router connects to, avoiding downtime and data usage overage charges
- Centralized cloud management through the Inseego Manage ™ cloud solution, which simplifies device configuration, installation, remote management, security and support, providing an excellent customer experience right “out of the box” and for the full product lifecycle
- Enterprise-grade security that includes WPA3 Wi-Fi security support, advanced encryption, Open VPN and IPsec VPN
- Added value with a robust pipeline of new features including WAN management, enterprise security, device management and vertical market applications.
The Wavemaker PRO 5G indoor router FG2000e can deliver gigabit-plus speeds (using sub-6 GHz 5G) that match or outperform typical cable and fiber optic speeds. The FG2000e is ideal for business offices, retail locations, medical facilities, campuses and remote job sites needing reliable, high-speed broadband access with features such as:
- A 5 Gbps ethernet port, additional LAN and WAN ports, and TS9 port for external antenna
- Wi-Fi 6 technology to support up to 128 Wi-Fi-enabled devices
- An RJ-11 port for optional Voice over LTE (VoLTE)
5G for private networks
According to IDC , the private LTE/5G equipment market will reach $5.7 Billion in 2024. “With more spectrum being made available for enterprise uses, coinciding with the arrival of commercial 5G, interest has grown toward using private LTE/5G solutions as a basis for connectivity across a multitude of mission-critical, industrial and traditional enterprise organizations.”
Inseego 5G: Fast, reliable and secure
Designed and developed in the U.S., Inseego 5G products deliver high speed and low latency with extensive cybersecurity, including WPA3 Wi-Fi security with advanced encryption, Open VPN, IPsec VPN, parental controls and more.
To learn more about Inseego 5G products and solutions go to inseego.com . For press and analyst inquires, please email press@inseego.com
* Pending carrier approval.
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Our innovative mobile broadband, fixed wireless access (FWA) solutions, and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of products that provide robust connectivity indoors, outdoors and in the harshest industrial environments.
Designed and developed in the USA, Inseego products and SaaS solutions build on the company’s patented technologies to provide the highest quality wireless connectivity for service providers, enterprises, and government entities worldwide. www.inseego.com #Putting5GtoWork
©2021 Inseego Corp. All rights reserved. The Inseego name and logo are registered trademarks, and the Wavemaker and Inseego Manage names are trademarks of Inseego Corp. Other Company, product or service names mentioned herein are the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005447/en/
Link:
Social Media:
https://www.facebook.com/Inseego/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom